JP Morgan analyst Brian Ossenbeck maintains Werner Enterprises (NASDAQ:WERN) with a Neutral and raises the price target from $42 to $43.
What’s Going On With Biodexa Pharmaceuticals Stock?
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment of Familial Adenomatous Polyposis.